Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study

Area of Science:

• Psychiatry
• Neuroscience
• Pharmacology

Background:

• Clozapine is a key treatment for refractory schizophrenia, but efficacy is often limited by persistent symptoms.
• Memantine, an NMDA receptor antagonist, has shown initial promise in augmenting clozapine therapy.
• Previous trials indicated short-term benefits of memantine on memory and negative symptoms.

Purpose of the Study:

• To evaluate the long-term efficacy and tolerability of memantine as an add-on therapy to clozapine.
• To assess the sustained effects on cognitive function, particularly memory and executive function.
• To monitor changes in positive and negative symptoms and overall clinical status.

Main Methods:

• An open-label, 1-year extension study involving patients who responded to a prior 12-week placebo-controlled trial.
• Participants received memantine augmentation to their clozapine treatment.
• Cognitive assessments included the Cambridge Neuropsychological Test Automated Battery; symptom severity was measured by the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression Severity Scale (CGI-S).

Main Results:

• Memory improvements observed in the initial trial were sustained throughout the 1-year extension.
• Significant improvements in PANSS negative, positive, and total symptoms were observed between 26 and 52 weeks.
• Executive function did not show significant improvement; memantine was well-tolerated with no serious adverse effects.

Conclusions:

• Adjunctive memantine therapy to clozapine provides sustained benefits for memory in patients with refractory schizophrenia.
• Long-term treatment with memantine leads to further significant improvements in negative, positive, and overall psychiatric symptoms.
• Memantine is a safe and effective augmentation strategy for clozapine-refractory schizophrenia, improving both cognitive and symptom domains.